Subjects: Biosimilar Pharmaceuticals - Digital Collections - National Library of Medicine Search Results

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

NLM Digital Collections

Start Over Subjects Biosimilar Pharmaceuticals

1. Questions and answers on biosimilar development and the BPCI Act

Publication:: Silver Spring, MD : Center for Drug Evaluation and Research, September 2021
Subject(s):: Biosimilar Pharmaceuticals
Drug Development
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration
United States.

2. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2022
Subject(s):: Biosimilar Pharmaceuticals
Drug Costs -- legislation & jurisprudence
Government Regulation
Medicare Part D -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

3. State biosimilar substitution laws could reduce consumer access and savings

Author(s):: Purvis, Leigh, author
McSpadden, James, author
Publication:: Washington, DC : AARP Public Policy Institute, October 2022
Subject(s):: Biosimilar Pharmaceuticals
Cost Savings
Health Services Accessibility
Legislation, Drug
Drug Costs
State Government
United States

4. Labeling for biosimilar products

Publication:: Silver Spring, MD : Center for Drug Evaluation and Research, July 2018
Subject(s):: Biosimilar Pharmaceuticals
Drug Labeling -- standards
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration